{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:17:12Z","timestamp":1791037032388,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.ygyno.2013.05.003","type":"journal-article","created":{"date-parts":[[2013,5,22]],"date-time":"2013-05-22T03:54:18Z","timestamp":1369194858000},"page":"329-333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Keeping it simple: Genetics referrals for all invasive serous ovarian cancers"],"prefix":"10.1016","volume":"130","author":[{"given":"R.","family":"Demsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"McCuaig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Maganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.J.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.R.","family":"Armel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2013.05.003_bb0005","series-title":"Canadian Cancer Statistics 2012","author":"Canadian Cancer Society's Steering Committee on Cancer Statistics","year":"2012"},{"key":"10.1016\/j.ygyno.2013.05.003_bb0010","series-title":"Cancer Facts & Figures 2012","author":"American Cancer Society","year":"2012"},{"issue":"11","key":"10.1016\/j.ygyno.2013.05.003_bb0015","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z","article-title":"The genetic attributable risk of breast and ovarian cancer","volume":"77","author":"Claus","year":"1996","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2013.05.003_bb0020","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0002-9378(98)70476-4","article-title":"BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing","volume":"178","author":"Rubin","year":"1998","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"10.1016\/j.ygyno.2013.05.003_bb0025","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2013.05.003_bb0030","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","article-title":"Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer","volume":"68","author":"Risch","year":"2001","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.ygyno.2013.05.003_bb0035","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ygyno.2011.10.027","article-title":"BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia","volume":"124","author":"Rodr\u00edguez","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2013.05.003_bb0040","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2011.01.020","article-title":"Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer","volume":"121","author":"Zhang","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"21","key":"10.1016\/j.ygyno.2013.05.003_bb0045","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2013.05.003_bb0050","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ygyno.2010.05.011","article-title":"Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube","volume":"118","author":"Vicus","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2013.05.003_bb0055","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0090-8258(03)00152-5","article-title":"Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in Israel","volume":"89","author":"Hirsh-Yechezkel","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"23","key":"10.1016\/j.ygyno.2013.05.003_bb0060","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jnci\/djj465","article-title":"Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada","volume":"98","author":"Risch","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.ygyno.2013.05.003_bb0065","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/AOG.0b013e31825f3576","article-title":"Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy","volume":"120","author":"Scrader","year":"2012","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.ygyno.2013.05.003_bb0070","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/AOG.0b013e3181a106d4","article-title":"ACOG Practice Bulletin No. 103: hereditary breast and ovarian cancer syndrome","volume":"113","author":"American College of Obstetricians and Gynecologists","year":"2009","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ygyno.2013.05.003_bb0075","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10897-007-9090-7","volume":"16","author":"Berliner","year":"2007","journal-title":"J Genet Couns"},{"key":"10.1016\/j.ygyno.2013.05.003_bb0080","author":"National Comprehensive Cancer Network (NCCN)"},{"issue":"4","key":"10.1016\/j.ygyno.2013.05.003_bb0085","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/JCO.2008.21.4684","article-title":"Preventing future cancers by testing women with ovarian cancer for BRCA mutations","volume":"28","author":"Kwon","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2013.05.003_bb0090","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2007.11.6905","article-title":"Effect of BRCA1\/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer","volume":"26","author":"Chetrit","year":"2008","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ygyno.2013.05.003_bb0095","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ygyno.2013.05.003_bb0100","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol"},{"issue":"9737","key":"10.1016\/j.ygyno.2013.05.003_bb0105","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2013.05.003_bb0110","author":"American College of Medical Genetics with Support from the New York State Department of Health"},{"issue":"2","key":"10.1016\/j.ygyno.2013.05.003_bb0115","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ygyno.2007.09.031","article-title":"Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions","volume":"107","author":"Lancaster","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2013.05.003_bb0120","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/0003-4819-143-5-200509060-00012","article-title":"U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force","volume":"143","author":"Nelson","year":"2005","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.ygyno.2013.05.003_bb0125","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"11","key":"10.1016\/j.ygyno.2013.05.003_bb0130","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2013.05.003_bb0135","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/IGC.0b013e3182392714","article-title":"Family history and women with ovarian cancer: is it asked and does it matter?: An observational study","volume":"22","author":"Lanceley","year":"2012","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2013.05.003_bb0140","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ygyno.2008.10.007","article-title":"Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study","volume":"112","author":"Metcalfe","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2013.05.003_bb0145","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ygyno.2008.06.016","article-title":"What women with ovarian cancer think and know about genetic testing","volume":"111","author":"Lacour","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2013.05.003_bb0150","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ygyno.2011.09.040","article-title":"There is no decision to make: experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer","volume":"124","author":"Meiser","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ygyno.2013.05.003_bb0155","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/AOG.0b013e3181da08d7","article-title":"Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities","volume":"115","author":"Meyer","year":"2010","journal-title":"Obstet Gynecol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813007361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813007361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T21:54:39Z","timestamp":1539640479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825813007361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0090825813007361"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.05.003","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Keeping it simple: Genetics referrals for all invasive serous ovarian cancers","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}